Nasdaq - Delayed Quote USD

Fidelity Disruptive Medicine Fund (FRXNX)

11.71
+0.11
+(0.95%)
At close: January 23 at 8:01:17 PM EST

Top 10 Holdings (38.19% of Total Assets)

SymbolCompany% Assets
Insulet Corporation 4.66%
Boston Scientific Corporation 4.36%
Penumbra, Inc. 3.99%
UnitedHealth Group Incorporated 3.90%
Humana Inc. 3.76%
Eli Lilly and Company 3.61%
Bruker Corporation 3.58%
Danaher Corporation 3.52%
Royalty Pharma plc 3.47%
Vertex Pharmaceuticals Incorporated 3.35%

Sector Weightings

SectorFRXNX
Healthcare   99.46%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 0.54%
Stocks 99.45%
Bonds 0.00%
Others 0.00%
Preferred 0.00%
Convertible 0.00%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average FRXNX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.19 5.28
Price/Sales 0.32 2.06
Price/Cashflow 0.05 17.54
Median Market Cap 22,410.37 34,862.81
3 Year Earnings Growth 5.76 32.48

Bond Holdings

Performance & Risk

YTD Return 6.65%
5y Average Return 0.00%
Rank in Category (ytd) 14
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.79
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Fidelity Investments
Net Assets 45.02M
YTD Return 6.65%
Yield 0.00%
Morningstar Rating
Inception Date Apr 16, 2020

Fund Summary

Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.

Related Tickers